Open Access
Optimal dose of losartan for renoprotection in diabetic nephropathy
Nephrology Dialysis TransplantationPeer ReviewedSteen Andersen2002Journals
Angiotensin II subtype-1 receptor antagonists represent a valuable new class of drugs in the treatment of diabetic nephropathy. The aim of our study was to evaluate the optimal dose of losartan for renoprotection and blood pressure reduction in diabetic nephropathy.

The content you want is available to Zendy users.

Already have an account? Sign in
Having issues? Contact support